TABLE 1

Demographic characteristics of preintervention versus intervention populations

Patient population demographicsValue (s)aP value
Preintervention (n = 247)Intervention (n = 233)
Age, yrs (mean ± SD)59.8 ± 15.156.3 ± 16.60.02
Female103 (41.7)87 (37.3)0.35
Comorbidities
    Malignancy107 (43.3)99 (42.5)0.93
    Chronic heart disease107 (43.3)80 (34.3)0.05
    Chronic kidney disease58 (23.5)59 (25.3)0.67
    Chronic lung disease42 (17.0)21 (9.0)0.01
    Chronic liver disease22 (8.9)30 (12.9)0.19
    Solid-organ transplant19 (7.7)25 (10.7)0.27
    Bone marrow transplant17 (6.9)20 (8.6)0.50
    HIV0 (0.0)0 (0.0)>0.99
Immunosuppression
    Chemotherapy within 90 days35 (14.2)47 (20.2)0.09
    Antirejection medications34 (13.8)41 (17.6)0.26
    Chronic corticosteroids27 (10.9)38 (16.3)0.11
    ANCb < 500 cell/μl7 (2.8)12 (5.2)0.24
    CD4 T cells < 200 cells/μl0 (0.0)0 (0.0)>0.99
Clinical status
    ICU admission91 (36.8)78 (33.5)0.45
    Hemodynamic instability requiring vasopressor support29 (11.7)30 (12.9)0.78
Source of bacteremia
    Central venous catheter51 (20.6)60 (25.8)0.20
    Intra-abdominal region49 (19.8)46 (19.7)>0.99
    Genitourinary region40 (16.2)36 (15.5)0.90
    SSTI/BJIc26 (10.5)26 (11.2)0.88
    Respiratory16 (6.5)11 (4.7)0.43
    Foreign device5 (2.0)6 (2.6)0.77
    Other9 (3.6)17 (7.3)0.11
    Unknown51 (20.6)31 (13.3)0.04
Complication
    Endocarditis9 (3.6)17 (7.3)0.11
    Metastatic seeding8 (3.2)6 (2.6)0.79
Type of acquisition
    Hospital acquired87 (35.2)80 (34.3)0.85
    Healthcare associated94 (38.1)65 (27.9)0.02
    Community acquired66 (26.7)88 (37.8)0.01
  • a Data represent number (percent) of patients unless otherwise indicated.

  • b ANC, absolute neutrophil count.

  • c SSTI, skin and soft tissue infection; BJI, bone and joint infection.